Sep 2026
Abstract B063: Exploring combination therapies to overcome RAS inhibitor resistance in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, due in large part to limited therapeutic options and the rapid emergence of treatment resistance. Despite the clinical success of recently developed RAS inhibitors (RASi) resistance to these agents , both mutant-specific and pan-RAS,...
Vasiliki I. Pantazopoulou, Casie S. Kubota, W. Jung et al.
· Cancer Research · 0 citations